New U S Cancer Drug Prices Rise 53% In Five Years -report towleroad.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from towleroad.com Daily Mail and Mail on Sunday newspapers.
By Deena Beasley (Reuters) - The annual price of a newly-launched cancer drug in the United States averaged $283,000 last year, a 53% increase from 20.
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
The drug was approved as a monotherapy for previously treated patients, a departure from approvals in the US and Japan for patients regardless of prior treatment.